Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

Taking stock of the drug industry, from the lab to the medicine chest

August 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jenny Kane/AP STAT+ | Medicare paid substantially more for J&J's Stelara when it was covered under Part D than under Part B Thanks to recent coverage changes, Stelara may cost beneficiaries even more because they will face higher out-of-pocket costs at pharmacies. By Ed Silverman STAT+ | A bespoke genetic therapy is helping Susannah. Can similar drugs be made at scale for other rare diseases? N-Lorem is showing it's scientifically feasible to develop personalized treatments for rare diseases, but access remains a challenge. By Jonathan Wosen MDMA therapy is facing an imminent FDA decision. Here's what you need to know The FDA is close to deciding whether to approve the prohibited psychedelic MDMA as a mainstream medical treatment. By Meghana Keshavan and Olivia Goldhill Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser